BioInvent International AB (OSTO:BINV)
kr 43.2 -0.05 (-0.12%) Market Cap: 2.84 Bil Enterprise Value: 1.80 Bil PE Ratio: 0 PB Ratio: 2.59 GF Score: 59/100

BioInvent International AB at Jefferies Healthcare Conference Transcript

Jun 08, 2023 / 05:00PM GMT
Release Date Price: kr19.5 (-0.71%)
Matt Galle
Jefferies - Analyst

Hi everyone, my name is Matt Galle, I'm part of the Jefferies healthcare banking team. It's my pleasure to welcome you to the Jefferies Global Healthcare Conference. With us today we have Martin Welschof, part of BioInvent, CEO of BioInvent, here to give you a presentation. I'm going to turn it over to him. Thank you.

Martin Welschof
BioInvent International AB - CEO

Thank you, Matt. And welcome, everybody. So this is our forward-looking statement and I will start with a quick snapshot of BioInvent.

So at BioInvent we are translating cancer biology into innovative immuno-oncology therapies and we are actually pushing ahead with a broad clinical portfolio, currently having five clinical programs running, soon six. And all these programs have been generated in-house since we are quite an integrated company. So we have a research engine that discovers targets and antibodies, we have our own manufacturing in-house, we can do up to 1,000 liter GMP, and obviously clinical development.

The technology that we use for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot